Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASAKBLF 93 3-1 Month Momentum % is -2.51% as of Sep. 13, 2026. GuruFocus rates AKBLF with a GF Score™ of 93/100 and a GF Value™ of $36.04 (Modestly Undervalued). Among 1,378 Biotechnology companies, Alk-Abello AS ranks worse than 81.28% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-13), Alk-Abello AS's 3-1 Month Momentum % is -2.51%.
The industry rank for Alk-Abello AS's 3-1 Month Momentum % or its related term are showing as below:
AKBLF's 3-1 Month Momentum % is ranked worse than 81.28% of 1378
companies
in the Biotechnology industry
Industry Median: 1.51
vs AKBLF: -2.51
Alk-Abello AS (OTCPK:AKBLF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Alk-Abello AS 3-1 Month Momentum % Related Terms
AKBLF vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Alk-Abello AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's 3-1 Month Momentum % falls into.
Alk-Abello AS (OTCPK:AKBLF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (AKBLF) has a 3-1 Month Momentum % of -2.51% as of Sep. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alk-Abello AS and its competitors. According to the industry distribution chart, Alk-Abello AS ranks #1120 out of 1378 companies in the Biotechnology industry, placing it in the top 81.3%.
Is Alk-Abello AS's 3-1 Month Momentum % too high?
Alk-Abello AS's current 3-1 Month Momentum % is -2.51%. Based on the distribution chart, Alk-Abello AS ranks #1120 out of 1378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alk-Abello AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #1120 out of 1378 companies for 3-1 Month Momentum %. This places Alk-Abello AS in the lower half of its industry. The industry median 3-1 Month Momentum % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.51, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current 3-1 Month Momentum % is -2.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (AKBLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $36.04, compared to a current price of $32.47 — trading 9.9% below its estimated fair value. The current 3-1 Month Momentum % is -2.51%. Alk-Abello AS's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Alk-Abello AS (AKBLF), the current 3-1 Month Momentum % is -2.51% as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (AKBLF) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued.
The current stock price of $32.47 is trading 9.9% below its estimated GF Value™ of $36.04.
GuruFocus considers Alk-Abello AS to be Modestly Undervalued.
Key valuation signals for AKBLF:
3-1 Month Momentum %: -2.51%
GF Value™: $36.04 vs. price of $32.47 (9.9% below fair value)
No single metric tells the full story. See the AKBLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
93GF Score
Get the complete analysis for AKBLF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKBLF has been successfully added to your 
